HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okada, J. Articles by Arimizu, N. Search for Related Content PubMed PubMed Citation Articles by Okada, J. Articles by Arimizu, N.

The Use of FDG-PET in the Detection and Management of Malignant Lymphoma: Correlation of Uptake with Prognosis

Department of Radiology, Chiba University, School of Medicine, Chiba, Japan

Correspondence: For reprints contact: Junichi Okada, MD, Department of Radiology, Chiba University, School of Medicine, 1-8-1 Inohana, Chiba City, 280 Japan.

ABSTRACT

Twenty-one patients with untreated malignant lymphoma in the head and neck region were evaluated with positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose (FDG) and gallium-67 SPECT imaging. Tumor-to-normal soft-tissue contrast ratios (TCRs) obtained 60 min after injection of FDG were higher than 2.6, and all malignant lymphomas were clearly visualized. In patients with poor prognosis, higher TCRs and glucose utilization rates (GURs) were observed, whereas low TCR and GUR were shown in a patient with low-grade malignancy. In comparison with ⁶⁷Ga scintigraphy, patients with high TCRs and GURs were likely to show increased accumulation of gallium-67, but accumulation of gallium-67 was not increased as much as FDG in poor prognostic patients. FDG-PET may be useful in the detection and management of malignant lymphoma.

This article has been cited by other articles:

				G. A. Ulaner, P. M. Colletti, and P. S. Conti B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience Radiology, March 1, 2008; 246(3): 895 - 902. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and D. J. Straus The Role of PET in Lymphoma J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334. [Abstract] [Full Text] [PDF]

				B. Mengiardi, H. Honegger, J. Hodler, U. G. Exner, M. D. Csherhati, and W. Bruhlmann Primary Lymphoma of Bone: MRI and CT Characteristics During and After Successful Treatment Am. J. Roentgenol., January 1, 2005; 184(1): 185 - 192. [Abstract] [Full Text] [PDF]

				C. Guay, M. Lepine, J. Verreault, and F. Benard Prognostic Value of PET Using 18F-FDG in Hodgkin's Disease for Posttreatment Evaluation J. Nucl. Med., August 1, 2003; 44(8): 1225 - 1231. [Abstract] [Full Text] [PDF]

				R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study Radiology, May 1, 2003; 227(2): 353 - 360. [Abstract] [Full Text] [PDF]

				M. Tatsumi, H. Kitayama, H. Sugahara, N. Tokita, H. Nakamura, Y. Kanakura, and T. Nishimura Whole-Body Hybrid PET with 18F-FDG in the Staging of Non-Hodgkin's Lymphoma J. Nucl. Med., April 1, 2001; 42(4): 601 - 608. [Abstract] [Full Text]

				H. Vesselle, R. A. Schmidt, J. M. Pugsley, M. Li, S. G. Kohlmyer, E. Vallières, and D. E. Wood Lung Cancer Proliferation Correlates with [F-18]Fluorodeoxyglucose Uptake by Positron Emission Tomography Clin. Cancer Res., October 1, 2000; 6(10): 3837 - 3844. [Abstract] [Full Text]

				R. Carr, S. F. Barrington, B. Madan, M. J. O'Doherty, C. A.B. Saunders, J. van der Walt, and A. R. Timothy Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography Blood, May 1, 1998; 91(9): 3340 - 3346. [Abstract] [Full Text] [PDF]